Radiopharmaceuticals Nuclear Medicine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Radiopharmaceuticals Nuclear Medicine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
(EMAILWIRE.COM, December 06, 2017 ) Global radiopharmaceuticals/nuclear medicine market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals//nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the radiopharmaceuticals/nuclear medicine market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-4H8Z4LpNMLEuOnnx
Global Radiopharmaceuticals/Nuclear Medicine Market:
Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radiotherapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-c654SbFYO64MsOhu
North America accounts for larger revenue share in global radiopharmaceuticals market
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-14mlyhjMGhVjZqa3
Competition Assessment
Key players profiled in the global Radiopharmaceuticals market include:
• Advanced Accelerator Applications S.A. (France)
• Bayer AG (Germany)
• Bracco Imaging S.p.A (Italy)
• Cardinal Health, Inc. (U.S.)
• Eli Lilly and Co. (U.S.)
• GE Healthcare (U.S.)
• IBA Molecular Imaging (Belgium)
• Jubilant Life Sciences Ltd (India)
• Lantheus Medical Imaging, Inc. (U.S.)
• Mallinckrodt plc (Ireland)
• Navidea Biopharmaceutical (U.S.)
• Nordion, Inc. (Canada)
• Siemens Healthineers (Germany)
Players in the radiopharmaceuticals market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals market.
Detailed Segmentation
By Product Type
• Diagnostic Radiopharmaceuticals
o SPECT Radiopharmaceuticals
o PET Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
o Beta Emitters
o Alpha emitters
o Brachytherapy
o Others
By Application
• Oncology
• Neurological disorders
• Cardiovascular diseases
• Thyroid
• Others
By Route of Administration
• Oral
• Inhalation
• Parenteral
By End User
• Hospitals
• Clinics
• Diagnostic Centers
• Research Institutes
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Website @https://www.precisionbusinessinsights.com
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-4H8Z4LpNMLEuOnnx
Global Radiopharmaceuticals/Nuclear Medicine Market:
Global radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radiotherapeutic and diagnostic procedures across the globe.
Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe
The global radiopharmaceutical market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period
Emergence of radiopharmaceuticals as safer alternative to the conventional diagnosis
The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-c654SbFYO64MsOhu
North America accounts for larger revenue share in global radiopharmaceuticals market
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-14mlyhjMGhVjZqa3
Competition Assessment
Key players profiled in the global Radiopharmaceuticals market include:
• Advanced Accelerator Applications S.A. (France)
• Bayer AG (Germany)
• Bracco Imaging S.p.A (Italy)
• Cardinal Health, Inc. (U.S.)
• Eli Lilly and Co. (U.S.)
• GE Healthcare (U.S.)
• IBA Molecular Imaging (Belgium)
• Jubilant Life Sciences Ltd (India)
• Lantheus Medical Imaging, Inc. (U.S.)
• Mallinckrodt plc (Ireland)
• Navidea Biopharmaceutical (U.S.)
• Nordion, Inc. (Canada)
• Siemens Healthineers (Germany)
Players in the radiopharmaceuticals market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals market.
Detailed Segmentation
By Product Type
• Diagnostic Radiopharmaceuticals
o SPECT Radiopharmaceuticals
o PET Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
o Beta Emitters
o Alpha emitters
o Brachytherapy
o Others
By Application
• Oncology
• Neurological disorders
• Cardiovascular diseases
• Thyroid
• Others
By Route of Administration
• Oral
• Inhalation
• Parenteral
By End User
• Hospitals
• Clinics
• Diagnostic Centers
• Research Institutes
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Website @https://www.precisionbusinessinsights.com
Contact Information:
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Precision Business Insights
Sales
Tel: +1-866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results